Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus First in man; Registrational; Therapeutic Use
  • Acronyms AURA; AURA extension; AURAext
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Sep 2019 Results of pooled subgroup analysis from Aura extension and Aura 2 studies, published in the Cancer Science.
    • 25 Mar 2019 The trial has been completed in Italy.
    • 04 Dec 2018 Results (n=411) of long term follow up from a pooled analysis of AURA I and Aura II studies published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top